Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67

NCT00216099 is registered in ClinicalTrials.gov with Christopher Sweeney, MBBS as lead sponsor.

NCT NCT00216099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67
Lead sponsor
Christopher Sweeney, MBBS
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
March 31, 2009
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer